| Background: Despite some advances, treatment of trigeminal neuralgia remains a signifcant challenge. This study
determines the efcacy and safety of autologous conditioned serum (Orthokine) injection into the foramen oval to
treat refractory trigeminal neuralgia.
Case presentation: This is a consecutive case series from the Pain and Palliative Care Department of Imam Reza
University Hospital, Tabriz, Iran. Eleven Iranian patients, eligible according to the inclusion and exclusion criteria,
aged 45.64 ±11.58 years (Four male and seven female, all Iranian) with established classical trigeminal neuralgia
were injected with Orthokine (2 mL per injection) once a week for three consecutive weeks (total of four injections).
Numeric rating scale scores for facial pain intensity and also carbamazepine daily dose were confrmed at pretreatment (T0) and at week 1 (T1), week 2 (T2), week 3 (T3), week 4 (T4), and month 2 (T5) posttreatment. Pain intensity was signifcantly reduced in the frst 3 weeks of follow-up in comparison with baseline (T0 to T3) (8.18 ± 1.99
to 2.82 ± 2.13, p < 0.001), an efect that was retained at week 4 (T4) and month 2 (T5) follow-ups (2.82 ± 2.13 to
3.36 ± 2.69, p = 0.886). Carbamazepine consumption was signifcantly reduced in the frst 3 weeks of follow-up in
comparison with baseline (T0 to T3) (636.36 ± 307.48 to 200.00 ± 296.64, p = 0.003), an efect that was retained
at week 4 and month 2 follow-ups (200.00 ± 296.64 to 200.00 ± 282.84, p = 0.802). There were no serious adverse
events in participants.
Conclusion: Orthokine injection led to consistent pain relief and reduced carbamazepine dosage in patients with
trigeminal neuralgia, with acceptable safety. |